CN115192634A - Lotus leaf powder solid beverage and preparation method thereof - Google Patents
Lotus leaf powder solid beverage and preparation method thereof Download PDFInfo
- Publication number
- CN115192634A CN115192634A CN202110402733.8A CN202110402733A CN115192634A CN 115192634 A CN115192634 A CN 115192634A CN 202110402733 A CN202110402733 A CN 202110402733A CN 115192634 A CN115192634 A CN 115192634A
- Authority
- CN
- China
- Prior art keywords
- lotus leaf
- parts
- solid beverage
- extract
- powder solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 87
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 86
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 84
- 235000013361 beverage Nutrition 0.000 title claims abstract description 39
- 239000007787 solid Substances 0.000 title claims abstract description 39
- 239000000843 powder Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 52
- 229930091371 Fructose Natural products 0.000 claims abstract description 27
- 239000005715 Fructose Substances 0.000 claims abstract description 27
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 27
- 229960004543 anhydrous citric acid Drugs 0.000 claims abstract description 26
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 20
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 20
- 208000007882 Gastritis Diseases 0.000 claims abstract description 17
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 17
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 17
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 16
- 230000009466 transformation Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims abstract description 10
- 230000000903 blocking effect Effects 0.000 claims abstract description 9
- 230000003902 lesion Effects 0.000 claims abstract description 8
- 230000002496 gastric effect Effects 0.000 claims abstract description 7
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 26
- 108010011485 Aspartame Proteins 0.000 claims description 18
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 18
- 239000000605 aspartame Substances 0.000 claims description 18
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 18
- 229960003438 aspartame Drugs 0.000 claims description 18
- 235000010357 aspartame Nutrition 0.000 claims description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 18
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 238000012327 Endoscopic diagnosis Methods 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a composition of a lotus leaf powder solid beverage for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesion, blocking gastritis cancer transformation and preventing gastric cancer and a preparation method thereof, wherein the preparation is one of a health-care product and a food. The preparation is prepared from lotus leaf extract, maltodextrin, crystalline fructose and the like as raw materials by the following method: crushing test tests of crystalline fructose and anhydrous citric acid prove that the lotus leaf powder solid beverage has good stability, good safety and complete preparation process.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine extracts, and particularly relates to a lotus leaf extract as a solid beverage for treating chronic atrophic gastritis, treating gastric precancerous lesions and/or blocking the occurrence of gastritis cancerization and a preparation method thereof.
Background
According to the statistics of cancer center data in China, more than half of tumor-related deaths in China are digestive system tumors [1]. The second and third tumor diseases of the stomach cancer and the colorectal cancer are located in China, and half of the stomach cancer is in China [2]. Digestive tract tumors are serious diseases which harm the life health of residents in China. The incidence of digestive tract tumor is high and has close relationship with various inflammations, including gastritis and gastric cancer, ulcerative colitis and colorectal cancer [3]. Prevention and control of digestive tract inflammatory cancer transformation is imminent. According to the statistics of the world health organization, the morbidity of the stomach diseases in the population reaches 80 percent, and 1.2 hundred million patients with intestinal tract diseases in China exist.
The incidence rate of gastric cancer is the first to be malignant tumor in rural areas, which seriously harms people's health. The occurrence of gastric cancer has a close relationship with gastritis, helicobacter pylori infection [4,5]. The prevalence rate of chronic gastritis in China exceeds 50%, and the prevalence rate of chronic gastritis based on endoscopic diagnosis is close to 90%. The malignant transformation from chronic gastritis to gastric cancer, namely 'gastritis-cancer transformation', is a key core of gastric cancer generation and is also a major breakthrough point for the antedisplacement of gastric cancer diagnosis and treatment. In recent years, the discovery of drugs having the action of treating chronic inflammation and blocking or inhibiting inflammatory cancer transformation has also been a major concern. The lotus leaf extract can fill the blank that the transformation of the digestive tract inflammatory cancer is difficult to reverse and treat clinically at present, realize the accurate prevention and control of the transformation of the digestive tract inflammatory cancer and assist the implementation of healthy Chinese strategies.
The lotus leaf is the leaf of Nelumbo nucifera Gaertn of Nymphaeaceae, also called lotus leaf and lotus root leaf, and is planted in the south and north of China. Lotus leaves are listed in the list of homologous Chinese medicines as food and medicine in document 45 of the ministry of health supervision of china (1991) beginning 11 months in 1991, and also in the list of homologous Chinese medicines as food and medicine published in 2018 of the recent committee on health and family planning. Lotus leaves have been reported to have biological activities of reducing blood lipid, losing weight, scavenging free radicals, etc. [6-8]. The inventor firstly discovers that nuciferine which is a main component in lotus leaves has an inhibiting effect on inflammatory cancer transformation through a network pharmacological method in earlier research, and obtains patent grant [9]. The lotus leaves are low in price and good in safety, the effective components of the lotus leaves for preventing and treating the gastritis cancer transformation are analyzed by the inventor through a network pharmacological method, the extraction process is provided, and the technical support is provided for clinically treating the chronic atrophic gastritis and blocking the gastritis cancer transformation.
Disclosure of Invention
According to one aspect of the invention, the composition and the preparation method of the lotus leaf powder solid beverage are provided for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesion, blocking gastritis cancer transformation and preventing gastric cancer.
According to another aspect of the present invention, there is provided a method for extracting a lotus leaf extract, comprising the steps of:
1) Cutting folium Nelumbinis decoction pieces with a medicine cutter, and mixing;
2) Putting the cut lotus leaf decoction pieces into an extraction tank, heating and refluxing for extraction for 1-5 times by taking water as a solvent, wherein the material-liquid ratio is 1-1;
3) Concentrating the combined filtrate for the first time by using a double-effect concentrator;
4) Performing secondary concentration on the concentrated solution after the primary concentration by using a vacuum scraper concentrator;
5) Drying the concentrated extract under reduced pressure by using a vacuum reduced pressure drying method or a spray drying method to obtain a dry extract;
6) Pulverizing the dry extract to 50-100 mesh to obtain folium Nelumbinis extract.
According to another aspect of the invention, the lotus leaf powder solid beverage or potion is characterized by being prepared from the following materials in parts by weight:
2.5 to 4 parts of lotus leaf extract,
3 to 5 portions of maltodextrin, 3 to 5 portions,
1-2 parts of crystalline fructose,
0.3 to 1 portion of sodium carboxymethyl cellulose,
0.1 to 0.5 portion of anhydrous citric acid,
0.04 to 0.08 portion of aspartame.
According to another aspect of the invention, the application of the lotus leaf extract in preparing a product for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesion and preventing gastric cancer is provided, and the product is one selected from medicines, health-care products and foods. The gastric cancer prevention includes at least one of treating chronic atrophic gastritis, protecting gastric mucosa, blocking gastritis cancer conversion, preventing gastritis from converting into gastric cancer, treating gastric precancerous lesion and preventing gastric cancer.
Drawings
Fig. 1 is a flow chart of a preparation process of a powdered lotus leaf solid beverage of example 1.
Fig. 2 is a flowchart of a preparation process of a powdered lotus leaf solid beverage of example 2.
Fig. 3 is a flowchart of a preparation process of a lotus leaf powder solid beverage of example 3.
Fig. 4 is a flowchart of a preparation process of a powdered lotus leaf solid beverage of example 4.
Fig. 5 is a flowchart of a preparation process of a powdered lotus leaf solid beverage of example 5.
Detailed Description
According to one aspect of the invention, the invention provides a novel medicinal and edible traditional Chinese medicine solid beverage for treating atrophic gastritis and precancerous lesions of gastric cancer and blocking conversion of gastritis and cancer and a preparation method thereof. The lotus leaf extract is derived from plant lotus leaf, and is obtained by water or organic solvent extraction.
According to another aspect of the present invention, there is provided a method for extracting a lotus leaf extract, comprising:
1) Cutting folium Nelumbinis decoction pieces with a medicine cutter, and mixing; wherein the lotus leaf decoction pieces are prepared lotus leaves;
2) Putting the cut lotus leaf decoction pieces into an extraction tank, heating and refluxing for extraction for 1-5 times by taking water as a solvent, wherein the material-liquid ratio is 1-1;
3) Concentrating the combined filtrate for the first time by using a double-effect concentrator;
4) Performing secondary concentration on the concentrated solution after the primary concentration by using a vacuum scraper concentrator;
5) Drying the concentrated extract by a spray drying method or a vacuum drying oven under reduced pressure to obtain a dry extract;
6) Pulverizing the dry extract to 50-100 mesh to obtain folium Nelumbinis extract.
According to another aspect of the invention, the application of the lotus leaf solid beverage in preparing the preparation for treating chronic atrophic gastritis, inhibiting gastritis cancer transformation and/or preventing gastric cancer is provided.
The prevention of tumorigenesis according to the present invention comprises: treating chronic atrophic gastritis, protecting gastric mucosa, blocking gastritis cancer transformation, treating gastric precancerous lesion, and preventing tumor.
In carrying out and carrying out the present invention, the present inventors conducted a series of experiments. The results of these tests are given in the following description of the examples. The experimental results show the preparation process and raw materials of the lotus leaf powder solid beverage.
According to another aspect of the invention, the lotus leaf powder solid beverage is characterized by being prepared from the following materials in parts by weight:
2.5 to 4 parts of lotus leaf extract,
3 to 5 portions of maltodextrin, 3 to 5 portions,
1-2 parts of crystalline fructose,
0.3 to 1 portion of sodium carboxymethyl cellulose,
0.1 to 0.5 portion of anhydrous citric acid,
0.04 to 0.08 portion of aspartame.
According to another aspect of the present invention, there is provided a preparation method of the lotus leaf powder solid beverage, comprising the following steps:
extracting the lotus leaf extract according to the extraction method, wherein the material-liquid ratio of 3 times of extraction is respectively 1;
crushing anhydrous citric acid and crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and crystalline fructose with a lotus leaf extract, maltodextrin, sodium carboxymethylcellulose and aspartame;
performing wet granulation on the uniformly mixed materials, wherein the adhesive is 65% ethanol, and the granulation mesh number is 12-40 meshes;
drying the prepared granules, grading and packaging.
The invention is illustrated below with reference to specific examples. It will be understood by those skilled in the art that these examples are merely illustrative of the present invention and do not limit the scope of the present invention in any way.
Example 1:
preparing a lotus leaf powder solid beverage, wherein the lotus leaf powder solid beverage is prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 4.72 parts of maltodextrin, 2 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.08 part of aspartame.
The preparation method of the lotus leaf powder solid beverage comprises the following steps:
(1) reflux extraction of the lotus leaf extract is carried out, wherein the extraction times are 3 times, the material-liquid ratio of 3 times of extraction is respectively 1. Filtering the extractive solution to obtain filtrate, concentrating the filtrate, and spray drying to obtain folium Nelumbinis extract;
(2) crushing the anhydrous citric acid and the crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and the crystalline fructose with the lotus leaf extract, the maltodextrin, the sodium carboxymethylcellulose and the aspartame;
(3) performing wet granulation on the uniformly mixed materials, wherein the adhesive is 65% ethanol, and the granulation mesh number is 12-40 meshes;
(4) drying the prepared granules, grading, and packaging.
Example 2:
preparing a lotus leaf powder solid beverage, wherein the lotus leaf powder solid beverage is prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 4.74 parts of maltodextrin, 2 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.06 part of aspartame.
The preparation of the lotus leaf powder solid beverage is carried out according to the following steps: extracting the lotus leaf extract according to the extraction method, wherein the extraction times are 3 times, the material-liquid ratio of the 3 times of extraction is respectively 1;
crushing anhydrous citric acid and crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and crystalline fructose with a lotus leaf extract, maltodextrin, sodium carboxymethylcellulose and aspartame;
granulating the uniformly mixed materials in one step, wherein the adhesive is water, and the granulation mesh number is 40-80 meshes;
drying the prepared granules, grading, and packaging.
Example 3:
preparing a lotus leaf powder solid beverage, wherein the lotus leaf powder solid beverage is prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 5.24 parts of maltodextrin, 1.5 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.06 part of aspartame.
(2) The preparation of the lotus leaf powder solid beverage is carried out according to the following steps:
performing the reflux extraction of the lotus leaf extract, wherein the extraction times are 3 times, the material-liquid ratio of the 3 times of extraction is respectively 1. Filtering the extractive solution to obtain filtrate, concentrating the filtrate, and vacuum drying under reduced pressure to obtain folium Nelumbinis extract;
crushing anhydrous citric acid and crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and crystalline fructose with a lotus leaf extract, maltodextrin, sodium carboxymethylcellulose and aspartame;
performing wet granulation on the uniformly mixed materials, wherein the adhesive is 65% ethanol, and the granulation mesh number is 14-40 meshes;
drying the prepared granules, grading, and packaging.
Example 4:
preparing a lotus leaf powder solid beverage, wherein the lotus leaf powder solid beverage is prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 4.76 parts of maltodextrin, 2 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.04 part of aspartame.
The preparation of the lotus leaf powder solid beverage is carried out according to the following steps:
performing the reflux extraction of the lotus leaf extract, wherein the extraction times are 3 times, the material-liquid ratio of the 3 times of extraction is respectively 1. Filtering the extractive solution to obtain filtrate, concentrating the filtrate, and spray drying to obtain folium Nelumbinis extract;
crushing anhydrous citric acid and crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and crystalline fructose with a lotus leaf extract, maltodextrin, sodium carboxymethylcellulose and aspartame;
granulating the uniformly mixed materials in one step, wherein the adhesive is 65% ethanol, and the grain size is 40-80 meshes;
drying the prepared granules, grading, and packaging.
Example 5:
preparing a lotus leaf powder solid beverage, wherein the lotus leaf powder solid beverage is prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 5.24 parts of maltodextrin, 1.5 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.06 part of aspartame.
The preparation of the lotus leaf powder solid beverage is carried out according to the following steps:
carrying out reflux extraction on the lotus leaf extract, wherein the extraction times are 3 times, the material-liquid ratio of 3 times of extraction is respectively 1. Filtering the extracting solution to obtain filtrate, and concentrating the filtrate into extract with the relative density of 1.1-1.2 g/mL;
crushing the anhydrous citric acid and the crystalline fructose into 80 meshes, and uniformly mixing the crushed anhydrous citric acid and the crystalline fructose with the lotus leaf extract, the maltodextrin, the sodium carboxymethylcellulose and the aspartame;
granulating the uniformly mixed materials and the extract in one step;
drying the prepared granules, grading, and packaging.
Reference documents:
1.Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015.CA:a Cancer Journal for Clinicians,2016,66(2):115-132.
2. xiongting, zhengrongshou, zanghongmei, etc., the epidemiological status of gastric cancer in China, clinical tumor in China, 2017, 44 (1): 52-58.
3.Crusz S M,Balkwill F R.Inflammation and cancer:advances and new agents.Nature Reviews Clinical Oncology,2015,12(10):584-96.
4.Ohata H,Kitauchi S,Yoshimura N,et al.Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer.International journal of cancer,2004,109(1):138-143.
5.Uemura N,Okamoto S,Yamamoto S,et al.Helicobacter pylori infection and the development of gastric cancer.New England Journal of Medicine,2001,345(11):784-789.
6. Research on blood lipid regulating effect of Zhulan Zhenjiang, liwei and folium Nelumbinis total alkaloid extract on hyperlipemia rats Heilongjiang medicine, 2010, 23 (3): 363-364.
7. The effect of the water decoction of pottery wave, shuaingjingxian, wufenglian and lotus leaf on the blood fat and blood rheology of the hyperlipidemic rat is reported in the Chinese materia medica, 2000, 28 (6): 55-56.
8. Qi, li Yan Wei, lotus leaf active chemical components and pharmacological research progress, chinese medicine research and information, 2005 (6): 22-24.
9. The invention relates to a Chinese invention patent ZL201310455974.4 and 2018.1.8.
Claims (10)
1. The extraction method of the lotus leaf extract is characterized by comprising the following steps:
1) Cutting folium Nelumbinis decoction pieces with a medicine cutter, and mixing; wherein the folium Nelumbinis decoction pieces are processed folium Nelumbinis;
2) Putting the cut lotus leaf decoction pieces into an extraction tank, heating and refluxing for extraction for 1-5 times by taking water as a solvent, wherein the material-liquid ratio is 1-1;
3) Carrying out primary concentration on the combined filtrate by using a double-effect concentrator;
4) Performing secondary concentration on the concentrated solution after the primary concentration by using a vacuum scraper concentrator;
5) Drying the concentrated extract under reduced pressure by using a vacuum reduced pressure drying method or a spray drying method to obtain a dry extract;
6) Pulverizing the dry extract to 50-100 mesh to obtain folium Nelumbinis extract.
2. The lotus leaf powder solid beverage is characterized by being prepared from the following materials in parts by weight:
2.5 to 4 parts of lotus leaf extract,
3-5 parts of maltodextrin, namely 3-5 parts of maltodextrin,
1-2 parts of crystalline fructose,
0.3 to 1 portion of sodium carboxymethyl cellulose,
0.1 to 0.5 portion of anhydrous citric acid,
0.04 to 0.08 portion of aspartame.
3. The lotus leaf powder solid beverage as claimed in claim 2, which is prepared from the following materials in parts by weight: 1.5-3.5 parts of lotus leaf extract, 4-6 parts of maltodextrin, 0.5-2.5 parts of crystalline fructose, 0.1-1 part of sodium carboxymethylcellulose, 0.1-0.5 part of anhydrous citric acid and 0.02-0.1 part of aspartame.
4. The lotus leaf powder solid beverage as claimed in claim 2, which is characterized by being prepared from the following materials in parts by weight: 2-3 parts of lotus leaf extract, 4.5-5.5 parts of maltodextrin, 1-2 parts of crystalline fructose, 0.3-0.7 part of sodium carboxymethylcellulose, 0.1-0.3 part of anhydrous citric acid and 0.04-0.08 part of aspartame.
5. The lotus leaf powder solid beverage as claimed in claim 2, which is characterized by being prepared from the following materials in parts by weight: 2.5 parts of lotus leaf extract, 5.24 parts of maltodextrin, 1.5 parts of crystalline fructose, 0.5 part of sodium carboxymethylcellulose, 0.2 part of anhydrous citric acid and 0.06 part of aspartame.
6. The lotus leaf powder solid beverage according to one of claims 2 to 5, wherein the lotus leaf powder solid beverage is used for at least one of treating chronic atrophic gastritis, protecting gastric mucosa, blocking gastritis cancer transformation, treating gastric precancerous lesion, and preventing occurrence of gastric cancer.
7. The method for preparing a powdered lotus leaf solid beverage according to any one of claims 2 to 6, characterized by comprising the steps of:
uniformly mixing the crushed anhydrous citric acid and the crystallized fructose with the lotus leaf extract, the maltodextrin, the sodium carboxymethylcellulose and the aspartame which are extracted by the extraction method according to claim 1;
granulating and drying the uniformly mixed materials;
and (4) finishing the prepared granules.
8. The preparation method according to claim 7, wherein the anhydrous citric acid and crystalline fructose in the step (2) have a crushed mesh number of 60 to 100 meshes.
9. The method of claim 7, wherein the granulation is one selected from a wet granulation method and a one-step granulation method.
10. A lotus leaf extract prepared by the preparation method according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110402733.8A CN115192634A (en) | 2021-04-14 | 2021-04-14 | Lotus leaf powder solid beverage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110402733.8A CN115192634A (en) | 2021-04-14 | 2021-04-14 | Lotus leaf powder solid beverage and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115192634A true CN115192634A (en) | 2022-10-18 |
Family
ID=83574298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110402733.8A Pending CN115192634A (en) | 2021-04-14 | 2021-04-14 | Lotus leaf powder solid beverage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115192634A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623211A (en) * | 2013-11-29 | 2014-03-12 | 成都九芝堂金鼎药业有限公司 | Preparation method of traditional Chinese medicinal pills for treating diabetes |
| CN106578899A (en) * | 2016-12-30 | 2017-04-26 | 贝克尔（天津）药业有限公司 | Instant cereal powder for improving male sperm motility |
| CN110393715A (en) * | 2018-09-13 | 2019-11-01 | 清华大学 | The application of drug occurs as preparation treatment atrophic gastritis and/or blocking gastritis cancer conversion for Nuciferine and Lotus Leafextract |
-
2021
- 2021-04-14 CN CN202110402733.8A patent/CN115192634A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623211A (en) * | 2013-11-29 | 2014-03-12 | 成都九芝堂金鼎药业有限公司 | Preparation method of traditional Chinese medicinal pills for treating diabetes |
| CN106578899A (en) * | 2016-12-30 | 2017-04-26 | 贝克尔（天津）药业有限公司 | Instant cereal powder for improving male sperm motility |
| CN110393715A (en) * | 2018-09-13 | 2019-11-01 | 清华大学 | The application of drug occurs as preparation treatment atrophic gastritis and/or blocking gastritis cancer conversion for Nuciferine and Lotus Leafextract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102030834A (en) | Method for extracting and preparing camellia polysaccharide from camellia and application of camellia polysaccharide | |
| CN101468944A (en) | Method for extracting and separating turmeric effective ingredient curcumin | |
| CN110393715B (en) | Application of nuciferine and folium Nelumbinis extract in preparing medicine for treating atrophic gastritis and/or blocking gastritis carcinogenesis | |
| CN103584098B (en) | Maca almond tablet and preparation method thereof | |
| CN101357192A (en) | Separation preparation method of gastrodia elata crude polysaccharide and gastrodia elata alcohol extract using fresh gastrodia elata as raw material | |
| CN112274541B (en) | Application of semiliquidambar cathayensis aqueous extract in preparation of antitumor drugs | |
| CN103145668A (en) | New technology for preparing luteolin by using hesperidin | |
| CN110066350A (en) | Blue or green money willow Polyose extraction and the method for blue or green money willow polysaccharide solid beverage preparation | |
| CN113041278A (en) | Method for extracting rape moss binding state polyphenol | |
| KR20020088211A (en) | Cartilage protective ingredients from medicinal plants and their composition | |
| CN105687422B (en) | Raspberry composition and application thereof | |
| CN115192634A (en) | Lotus leaf powder solid beverage and preparation method thereof | |
| CN101875648A (en) | Method for extracting and purifying Pinostrobin from medicinal plants, and pharmaceutical preparation and application thereof | |
| CN113429452B (en) | Acylated mogroside derivatives as anti-inflammatory agents and anti-inflammatory compositions | |
| CN115403457A (en) | Preparation method of turmeric extract | |
| CN108157545A (en) | A kind of guava leaf liquid beverage and preparation method thereof | |
| CN104147309A (en) | Dunaliella salina nutrition composition and preparation method thereof | |
| CN105456308B (en) | Pinus massoniana lamb bark extract for treating squamous cell lung carcinoma, and preparation method and composition thereof | |
| CN112755168A (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by helicobacter pylori and preparation method and application thereof | |
| JP4030495B2 (en) | Antiallergic agent | |
| CN101390979B (en) | Raisin tree seed extract and preparation method and use thereof in preparing anti-tumor medicine | |
| CN114601891B (en) | Composition with anti-ulcerative colitis effect and preparation method thereof | |
| CN107629868A (en) | The supercritical extraction process of tea-seed oil | |
| CN103599271B (en) | A kind of Chinese medicine for the treatment of hysteromyoma | |
| KR100391195B1 (en) | a manufacturing technique of a beverage using of an educt which is distilled from Liriope spicata Lour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221018 |
|
| RJ01 | Rejection of invention patent application after publication |